Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/783,680external-prioritypatent/US8642756B2/en
Priority claimed from EP11714465.9Aexternal-prioritypatent/EP2552930B1/en
Application filed by Gilead Pharmasset LlcfiledCriticalGilead Pharmasset Llc
Publication of CY1116976T1publicationCriticalpatent/CY1116976T1/en
Αποκαλύπτονται εις το παρόν φωσφοραμιδικά νουκλεοζιδίων και η χρήση αυτών ως παράγοντες για αγωγή ιικών παθήσεων. Αυτές οι ενώσεις είναι αναστολείς της εξαρτώμενης από RNA ιικής αντιγραφής RNA και είναι χρήσιμες ως αναστολείς της πολυμεράσης του NS5B του HCV, ως αναστολείς της αντιγραφής του HCV και για την αγωγή της λοίμωξης από ηπατίτιδα C σε θηλαστικά.The phosphoramid nucleoside nucleosides and their use as agents for the treatment of viral diseases are disclosed herein. These compounds are inhibitors of RNA-dependent viral RNA replication and are useful as inhibitors of HCV NS5B polymerase, as inhibitors of HCV replication, and for the treatment of hepatitis C infection in mammals.
Crystalline form of propanoate of (s) - isopropyl 2 - (((s) - (((2r, 3r, 4r, 5r) - 5- (2,4-dioxo-3,4-dihydropyrimidim-1 (2h) - il) -4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl) methoxy) (phenoxy) phosphoryl) amino); Preparation process; framaceutic composition; and its use for the treatment of an infection caused by the hepatitis c virus.